{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T03:06:07Z","timestamp":1771038367240,"version":"3.50.1"},"reference-count":54,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>Unlike in non-surgical settings, many centres continue to favour vitamin K antagonists (VKAs) for stroke prevention in atrial fibrillation (AF) following major cardiac surgery. Current guidelines indicate insufficient data on the use of direct oral anticoagulants (DOACs) early after cardiac surgery. This study aims to evaluate whether DOACs are non-inferior to VKAs in terms of efficacy and safety for stroke prevention in post-operative AF.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>MEDLINE, EMBASE, CENTRAL, and Clinicaltrials.gov were searched from inception till 2 July 2024, and relevant reviews were screened as grey literature. Studies comparing DOACs with VKAs for stroke prevention in patients with (post-operative) AF after major cardiac surgery were included. Studies on patients with mechanical valve replacement or moderate to severe mitral stenosis were excluded. Outcomes of interest included thromboembolic events, major bleeding and mortality up to 6 months after cardiac surgery. Eleven studies, including two randomized controlled trials, reporting on &amp;gt;18,000 patients were analyzed. There were no significant differences between DOACs and VKAs in thromboembolic events (OR: 0.96; CI: 0.62\u20131.50; I2: 0%), any stroke (OR: 1.44; CI: 0.61\u20133.41; I2: 0%), major bleeding (OR: 0.97; CI: 0.60\u20131.56; I2: 48%), all-cause mortality (OR: 1.00; CI: 0.73\u20131.37; I2: 0%) or admission duration (MD: \u22120.33; CI: \u22121.16\u20130.49; I2: 0%) in the first 6 months after cardiac surgery.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>There is no high-quality evidence that DOACs and VKAs differ in efficacy or safety for stroke prevention in AF after cardiac surgery. While awaiting high-quality randomized data, our meta-analysis found no evidence to support routinely avoiding DOACs or favouring VKAs in this setting.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Registration<\/jats:title>\n                  <jats:p>Review registration number: CRD42023412592.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ehjopen\/oeaf062","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T18:21:43Z","timestamp":1749061303000},"source":"Crossref","is-referenced-by-count":3,"title":["Does the type of oral anticoagulant matter for stroke prevention or bleeding in patients with atrial fibrillation after cardiac surgery? A systematic review and meta-analysis"],"prefix":"10.1093","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9800-9550","authenticated-orcid":false,"given":"Marc M","family":"Terpstra","sequence":"first","affiliation":[{"name":"Department of Clinical and Experimental Cardiology, Heart Center, Amsterdam University Medical Centers, University of Amsterdam , Meibergdreef 9, 1105 AZ Amsterdam ,","place":["The Netherlands"]},{"name":"Amsterdam Cardiovascular Sciences, Heart Failure and Arrhythmias , Meibergdreef 9, 1105AZ Amsterdam ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1392-8193","authenticated-orcid":false,"given":"Tim A C","family":"de Vries","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Cardiology, Heart Center, Amsterdam University Medical Centers, University of Amsterdam , Meibergdreef 9, 1105 AZ Amsterdam ,","place":["The Netherlands"]},{"name":"Amsterdam Cardiovascular Sciences, Heart Failure and Arrhythmias , Meibergdreef 9, 1105AZ Amsterdam ,","place":["The Netherlands"]},{"name":"Department of Cardiology, Rijnstate Hospital , Wagnerlaan 55, 6815 AD Arnhem ,","place":["The Netherlands"]},{"name":"Department of Clinical Geriatrics, Radboud University Medical Centre , Geert Grooteplein Zuid 10, 6525 GA Nijmegen ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5917-8716","authenticated-orcid":false,"given":"Ellis","family":"Oortwijn","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Cardiology, Heart Center, Amsterdam University Medical Centers, University of Amsterdam , Meibergdreef 9, 1105 AZ Amsterdam ,","place":["The Netherlands"]},{"name":"Amsterdam Cardiovascular Sciences, Heart Failure and Arrhythmias , Meibergdreef 9, 1105AZ Amsterdam ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7626-7711","authenticated-orcid":false,"given":"Rob A F","family":"de Lind van Wijngaarden","sequence":"additional","affiliation":[{"name":"Amsterdam Cardiovascular Sciences, Heart Failure and Arrhythmias , Meibergdreef 9, 1105AZ Amsterdam ,","place":["The Netherlands"]},{"name":"Department of Cardiothoracic Surgery, Heart Center, Amsterdam University Medical Centers , Meibergdreef 9, 1105 AZ Amsterdam ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8122-7017","authenticated-orcid":false,"given":"Joris R","family":"de Groot","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Cardiology, Heart Center, Amsterdam University Medical Centers, University of Amsterdam , Meibergdreef 9, 1105 AZ Amsterdam ,","place":["The Netherlands"]},{"name":"Amsterdam Cardiovascular Sciences, Heart Failure and Arrhythmias , Meibergdreef 9, 1105AZ Amsterdam ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,6,4]]},"reference":[{"key":"2025062713214388600_oeaf062-B1","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1161\/CIRCULATIONAHA.111.019893","article-title":"Atrial fibrillation pathophysiology: implications for management","volume":"124","author":"Iwasaki","year":"2011","journal-title":"Circulation"},{"key":"2025062713214388600_oeaf062-B2","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","article-title":"Atrial fibrillation as an independent risk factor for stroke: the Framingham study","volume":"22","author":"Wolf","year":"1991","journal-title":"Stroke"},{"key":"2025062713214388600_oeaf062-B3","doi-asserted-by":"crossref","first-page":"351","DOI":"10.4330\/wjc.v3.i11.351","article-title":"Incidence, clinical impact and risk of bleeding during oral anticoagulation therapy","volume":"3","author":"Rubboli","year":"2011","journal-title":"World J Cardiol"},{"key":"2025062713214388600_oeaf062-B4","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"2025062713214388600_oeaf062-B5","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1161\/CIRCRESAHA.116.306925","article-title":"Evolving treatments for arterial and venous thrombosis: role of the direct oral anticoagulants","volume":"118","author":"Chan","year":"2016","journal-title":"Circ Res"},{"key":"2025062713214388600_oeaf062-B6","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1016\/j.jtcvs.2021.03.059","article-title":"Nonvitamin K oral anticoagulants in cardiac surgery: what cardiothoracic surgeons need to know 2.0","volume":"163","author":"Waterford","year":"2022","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2025062713214388600_oeaf062-B7","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1093\/europace\/euw208","article-title":"Non-vitamin K oral anticoagulants in patients with atrial fibrillation after cardiac surgery: the results of the European Heart Rhythm Association survey","volume":"18","author":"Vranckx","year":"2016","journal-title":"Europace"},{"key":"2025062713214388600_oeaf062-B8","doi-asserted-by":"crossref","first-page":"e035708","DOI":"10.1161\/JAHA.124.035708","article-title":"Ten-year trend of oral anticoagulation use in postoperative and nonpostoperative atrial fibrillation in routine clinical practice","volume":"13","author":"Yao","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"2025062713214388600_oeaf062-B9","first-page":"ivae089","article-title":"Antithrombotic therapy after heart valve surgery: contemporary practice in the UK","volume":"38","author":"Laskar","year":"2024","journal-title":"Interdiscip Cardiovasc Thorac Surg"},{"key":"2025062713214388600_oeaf062-B10","doi-asserted-by":"publisher","DOI":"10.1111\/ans.70045","article-title":"Early use of non-vitamin K antagonist oral anticoagulants after cardiac surgery compared with warfarin for postoperative atrial fibrillation","author":"Chang","year":"2025","journal-title":"ANZ J Surg"},{"key":"2025062713214388600_oeaf062-B11","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.athoracsur.2023.11.031","article-title":"Anticoagulant prescribing patterns in new-onset atrial fibrillation after cardiac surgery","volume":"117","author":"Krahn","year":"2024","journal-title":"Ann Thorac Surg"},{"key":"2025062713214388600_oeaf062-B12","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1161\/CIRCULATIONAHA.122.060315","article-title":"Oral anticoagulation use and left atrial appendage occlusion in LAAOS III","volume":"148","author":"Connolly","year":"2023","journal-title":"Circulation"},{"key":"2025062713214388600_oeaf062-B13","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"45","author":"Van Gelder","year":"2024","journal-title":"Eur Heart J"},{"key":"2025062713214388600_oeaf062-B14","doi-asserted-by":"crossref","first-page":"ezae355","DOI":"10.1093\/ejcts\/ezae355","article-title":"2024 EACTS guidelines on perioperative medication in adult cardiac surgery","volume":"67","author":"Authors\/Task Force members","year":"2024","journal-title":"Eur J Cardiothorac Surg"},{"key":"2025062713214388600_oeaf062-B15","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"23","author":"Steffel","year":"2021","journal-title":"Europace"},{"key":"2025062713214388600_oeaf062-B16","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa2029603","article-title":"Rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve","volume":"383","author":"Guimar\u00e3es","year":"2020","journal-title":"N Engl J Med"},{"key":"2025062713214388600_oeaf062-B17","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jtcvs.2021.01.127","article-title":"Efficacy and safety of edoxaban in patients early after surgical bioprosthetic valve implantation or valve repair: a randomized clinical trial","volume":"165","author":"Shim","year":"2023","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2025062713214388600_oeaf062-B18","doi-asserted-by":"crossref","first-page":"euae298","DOI":"10.1093\/europace\/euae298","article-title":"Spotlight on the 2024 ESC\/EACTS management of atrial fibrillation guidelines: 10 novel key aspects","volume":"26","author":"Rienstra","year":"2024","journal-title":"Europace"},{"key":"2025062713214388600_oeaf062-B19","volume-title":"Warfarin","author":"Patel","year":"2025"},{"key":"2025062713214388600_oeaf062-B20","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"2025062713214388600_oeaf062-B21","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1053\/j.semtcvs.2021.05.011","article-title":"Safety of direct oral anticoagulants compared to warfarin for atrial fibrillation after cardiac surgery: a systematic review and meta-analysis","volume":"34","author":"Hage","year":"2022","journal-title":"Semin Thorac Cardiovasc Surg"},{"key":"2025062713214388600_oeaf062-B22","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.bja.2022.05.010","article-title":"Direct oral anticoagulants in atrial fibrillation following cardiac surgery: a systematic review and meta-analysis with trial sequential analysis","volume":"129","author":"Koh","year":"2022","journal-title":"Br J Anaesth"},{"key":"2025062713214388600_oeaf062-B23","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jclinepi.2021.03.001","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"134","author":"Page","year":"2021","journal-title":"J Clin Epidemiol"},{"key":"2025062713214388600_oeaf062-B24","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"2025062713214388600_oeaf062-B25"},{"key":"2025062713214388600_oeaf062-B26","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/jrsm.1122","article-title":"Combining randomized and non-randomized evidence in clinical research: a review of methods and applications","volume":"6","author":"Verde","year":"2015","journal-title":"Res Synth Methods"},{"key":"2025062713214388600_oeaf062-B27","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"2025062713214388600_oeaf062-B28","volume-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team","year":"2024"},{"key":"2025062713214388600_oeaf062-B29","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting meta-analyses in {R} with the {metafor} package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J Stat Softw"},{"key":"2025062713214388600_oeaf062-B30","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1686","article-title":"Metamedian: an R package for meta-analyzing studies reporting medians","volume":"15","author":"McGrath","year":"2024","journal-title":"Res Syn Methods"},{"key":"2025062713214388600_oeaf062-B31","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/bimj.201900036","article-title":"Meta-analysis of the difference of medians","volume":"62","author":"McGrath","year":"2020","journal-title":"Biom J"},{"key":"2025062713214388600_oeaf062-B32","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1177\/1074248420929483","article-title":"Comparison of anticoagulants for postoperative atrial fibrillation after coronary artery bypass grafting: a pilot study","volume":"25","author":"Chapin","year":"2020","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"2025062713214388600_oeaf062-B33","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.amjsurg.2015.07.005","article-title":"Novel oral anticoagulants vs warfarin for the management of postoperative atrial fibrillation: clinical outcomes and cost analysis","volume":"210","author":"Anderson","year":"2015","journal-title":"Am J Surg"},{"key":"2025062713214388600_oeaf062-B34","doi-asserted-by":"crossref","first-page":"10742484221128124","DOI":"10.1177\/10742484221128124","article-title":"Impact of COVID-19 on the prescribing pattern of oral anticoagulants for atrial fibrillation after cardiac surgery","volume":"27","author":"Brochu","year":"2022","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"2025062713214388600_oeaf062-B35","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jtcvs.2023.03.004","article-title":"Direct oral anticoagulants for atrial fibrillation in early postoperative valve repair or bioprosthetic replacement","volume":"168","author":"Moser","year":"2023","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2025062713214388600_oeaf062-B36","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/j.athoracsur.2020.12.031","article-title":"Non-vitamin K antagonist oral anticoagulant vs warfarin for post cardiac surgery atrial fibrillation","volume":"112","author":"Nauffal","year":"2021","journal-title":"Ann Thorac Surg"},{"key":"2025062713214388600_oeaf062-B37","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s40261-020-00939-x","article-title":"Comparison of the efficacy and safety of direct oral anticoagulants and warfarin after bioprosthetic valve replacements","volume":"40","author":"Pasciolla","year":"2020","journal-title":"Clin Drug Investig"},{"key":"2025062713214388600_oeaf062-B38","doi-asserted-by":"crossref","first-page":"355","DOI":"10.5603\/CJ.a2021.0158","article-title":"NOAC versus warfarin in the treatment of atrial fibrillation during the first three months after bioprosthetic aortic valve replacement","volume":"29","author":"Piepiorka-Broniecka","year":"2022","journal-title":"Cardiol J"},{"key":"2025062713214388600_oeaf062-B39","doi-asserted-by":"crossref","first-page":"e002602","DOI":"10.1136\/openhrt-2024-002602","article-title":"Thromboembolic and bleeding events after valvular intervention in patients with atrial fibrillation","volume":"11","author":"Skogseid","year":"2024","journal-title":"Open Heart"},{"key":"2025062713214388600_oeaf062-B40","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1016\/j.hlc.2020.04.018","article-title":"Novel oral anticoagulants compared to warfarin for postoperative atrial fibrillation after isolated coronary artery bypass grafting","volume":"29","author":"Woldendorp","year":"2020","journal-title":"Heart Lung Circ"},{"key":"2025062713214388600_oeaf062-B41","doi-asserted-by":"crossref","first-page":"490","DOI":"10.5858\/2009-0474-OA.1","article-title":"International normalized ratio versus plasma levels of coagulation factors in patients on vitamin K antagonist therapy","volume":"135","author":"Gulati","year":"2011","journal-title":"Arch Pathol Lab Med"},{"key":"2025062713214388600_oeaf062-B42","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1161\/01.CIR.38.1.169","article-title":"Studies on coumarin anticoagulant drugs. Initiation of warfarin therapy without a loading dose","volume":"38","author":"O'Reilly","year":"1968","journal-title":"Circulation"},{"key":"2025062713214388600_oeaf062-B43","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.thromres.2014.05.035","article-title":"Meta-analysis to assess the quality of international normalized ratio control and associated outcomes in venous thromboembolism patients","volume":"134","author":"Mearns","year":"2014","journal-title":"Thromb Res"},{"key":"2025062713214388600_oeaf062-B44","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s12471-019-01346-4","article-title":"Experience with non-vitamin K antagonists in The Netherlands: stories from both sides of the desk","volume":"27","author":"de Vries","year":"2019","journal-title":"Neth Heart J"},{"key":"2025062713214388600_oeaf062-B45","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1182\/asheducation-2016.1.605","article-title":"Reversing vitamin K antagonists: making the old new again","volume":"2016","author":"Eichinger","year":"2016","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"2025062713214388600_oeaf062-B46","doi-asserted-by":"crossref","first-page":"314","DOI":"10.7861\/clinmedicine.18-4-314","article-title":"The reversal of anticoagulation in clinical practice","volume":"18","author":"Thomas","year":"2018","journal-title":"Clin Med (Lond)"},{"key":"2025062713214388600_oeaf062-B47","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1182\/blood-2017-05-782060","article-title":"Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study","volume":"130","author":"Majeed","year":"2017","journal-title":"Blood"},{"key":"2025062713214388600_oeaf062-B48","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1056\/NEJMoa1814051","article-title":"Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors","volume":"380","author":"Connolly","year":"2019","journal-title":"N Engl J Med"},{"key":"2025062713214388600_oeaf062-B49","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1182\/asheducation-2016.1.612","article-title":"Reversal of direct oral anticoagulants: a practical approach","volume":"2016","author":"Shih","year":"2016","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"2025062713214388600_oeaf062-B50","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13049-019-0625-3","article-title":"Application of prothrombin complex concentrate for reversal of direct oral anticoagulants in clinical practice: indications, patient characteristics and clinical outcomes compared to reversal of vitamin K antagonists","volume":"27","author":"Muller","year":"2019","journal-title":"Scand J Trauma Resusc Emerg Med"},{"key":"2025062713214388600_oeaf062-B51","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1056\/NEJMoa1707278","article-title":"Idarucizumab for dabigatran reversal\u2014full cohort analysis","volume":"377","author":"Pollack","year":"2017","journal-title":"N Engl J Med"},{"key":"2025062713214388600_oeaf062-B52","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/eurheartj\/ehab395","article-title":"2021 ESC\/EACTS guidelines for the management of valvular heart disease","volume":"43","author":"Vahanian","year":"2022","journal-title":"Eur Heart J"},{"key":"2025062713214388600_oeaf062-B53","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"key":"2025062713214388600_oeaf062-B54","author":"NHR"}],"container-title":["European Heart Journal Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjopen\/advance-article-pdf\/doi\/10.1093\/ehjopen\/oeaf062\/63436700\/oeaf062.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjopen\/article-pdf\/5\/3\/oeaf062\/63436700\/oeaf062.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjopen\/article-pdf\/5\/3\/oeaf062\/63436700\/oeaf062.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T17:21:53Z","timestamp":1751044913000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjopen\/article\/doi\/10.1093\/ehjopen\/oeaf062\/8156819"}},"subtitle":[],"editor":[{"given":"Frieder","family":"Braunschweig","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,4,30]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,4,30]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjopen\/oeaf062","relation":{},"ISSN":["2752-4191"],"issn-type":[{"value":"2752-4191","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2025,4,30]]},"article-number":"oeaf062"}}